Ranbaxy Laboratories Ltd unveiled an advanced Cephalosporin, Cefprozil, under the brand name Refzil O.
The Supreme Court has asked the Andhra Pradesh High Court to take a decision within two days on a plea challenging merger of Sun Pharmaceutical with Ranbaxy.
They seek to profit from big-selling drugs going off-patent this year in the lucrative market.
US drug regulator's fiat on Mohali factory, after strictures on the two other major Indian units, has numerous negative implications.
For Sun Pharma, it is an astute purchase that it hopes will not only boost its position in India but also globally.
Ranbaxy Laboratories on Wednesday reported widening of its consolidated net loss to Rs 1,029.72 crore (Rs 10.29 billion) for the third quarter ended December 31, 2014
Finance Minister P Chidambaram has asked the Income Tax department to focus on the companies that pay less than effective tax rate of 24 per cent.
Apollo Pharmacy, the country's largest branded drug retail network with over 1,500 outlets, has temporarily suspended sale of medicines manufactured by Ranbaxy Laboratories. It has also stopped further procurement from the company for now.
An advocate on Wednesday approached the Supreme Court with a PIL seeking cancellation of the license granted to Ranbaxy Laboratories and for initiating probe against the pharma major for allegedly manufacturing and selling adulterated drugs.
Patient safety and quality our guidance now, says CEO and MD Arun Sawhney.
Ranbaxy Laboratories Ltd said it has not taken any decision regarding sale of its chemical unit
The generic drugs at issue were manufactured at Ranbaxy's facilities in Paonta Sahib and Dewas in India and included acne drug Sotret, epilepsy and nerve pain drug gabapentin and antibiotic ciprofloxacin.
With local companies facing stress in domestic operations, valuations are down.
Many say trend could lead to concerns on manufacturing quality in Indian facilities.
Though independent directors acted in a manner less than desirable, they might not be held responsible.
Both the companies intend to integrate their business operations in Thailand to leverage and maximise the synergies of hybrid business model, which is expected to commence business on April 1, 2013, Ranbaxy said in a statement on Wednesday.
This helps consumers check the authenticity of drugs simply by sending SMSes.
The US FDA, during its inspection of Ranbaxy's manufacturing facilities in India, between 2006 and 2008, had found violations, incomplete testing records and an inadequate stability programme, besides manufacturing practices that did not follow regulations.
Indian firms raised the money via external commercial borrowings.
Firm pleads guilty to lying to US FDA; says it had set aside the money.
If it gets the USFDA nod, the sales would help to pull the company out of the red.
Two individuals filed the petition in the high court of Andhra Pradesh
It has hired consultants to advise it on a strategic project and compliance issues in the US. It also needs to improve employee morale.
The 2008 deal agreement contains provisions of arbitration to be held in that country.
The company was indicted for violations at one of its US facilities in 2009, even after Daiichi Sankyo took over as majority shareholder in 2008.
Tech Mahindra and United Spirits will replace them in the 50-share index of the National Stock Exchange with effect from March 28.
In what could be the beginning of fresh troubles for Ranbaxy Laboratories, which has just managed to settle long-pending issues with the US Department of Justice after agreeing to pay a penalty of $500 million, the health ministry in India, too, has decided to initiate a probe.
Less than three months after roaring into us market with generic for cholesterol-reducing Lipitor, Dept of Justice files for permanent injunction against Ranbaxy.
Work to begin after that on corrective measures to meet US regulator's requirements.
Regulator says fee would enable it to quicken approval process.
Ranbaxy Laboratories Ltd said it has not received any notice from National Pharmaceutical Pricing Authority to deposit Rs 15 million as penalty for pricing flaws.
Ranbaxy requested withdrawal of approval under a consent decree.
The decline in these was mostly due to company or sector-specific issues, say experts.
The United States Food and Drugs Administration has granted Ranbaxy Laboratories a tentative approval to market a generic form of Bristol-Myers' anti-depressant Serzone, US FDA's web site said.
It has exited most non-profitable geographies and is no longer chasing acquisitions. Will the new strategy pay off?
Drug major Sun Pharmaceutical Industries has acquired US-based Pharmalucence Inc for an undisclosed amount.
Ranbaxy was scheduled to launch its drug on September 21, the day Diovan's patent expired.
Ranbaxy has also agreed to relinquish any 180-day marketing exclusivity that it might have for three pending generic drug applications.
This move could cost $299 million a year for Indian pharma players.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances